Sichuan Huiyu Pharmaceutical Co. Ltd. and Sichuan Huiyu Seacross Pharmaceutical Tech Co. Ltd. have divulged new polycyclic lysine-specific histone demethylase 1A (KDM1A, LSD1) inhibitors reported to be useful for the treatment of small-cell lung cancer (SCLC).
Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have identified new fused tetracyclic mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1, HPK1, MEKKK1) inhibitors reported to be useful for the treatment of cancer, diabetes, inflammation, infections, neurodegeneration and autoimmune, cardiovascular and reproductive disorders.
Researchers at the University of Queensland have been awarded funding to advance work across mRNA research, cancer vaccines and single-cell genomic technologies.
Biomea Fusion Inc. has received IND clearance from the FDA to begin a phase I/Ib trial of BMF-219, a selective, covalent menin inhibitor in patients with unresectable, locally advanced, or metastatic non-small-cell lung cancer (NSCLC), colorectal cancer, or pancreatic ductal adenocarcinoma with an activating KRAS mutation.
Akeso Inc. has received approval from China's National Medical Products Administration (NMPA) for a phase Ib/II trial of ivonescimab (AK-112) combined with drebuxelimab (AK-119) for the treatment of advanced solid tumors.
PT Etana Biotechnologies Indonesia secured a series B financing of undisclosed value, led by Chinese investors that include Jack Ma’s Yunfeng Capital and Highlight Capital. The funds will be used to strengthen the company's pipeline and to expand its local manufacturing capacity.
Mablink Bioscience SAS raised €31 million (US$30.3 million) in a series A funding round and set its sights on a phase I trial of its lead next-generation antibody-drug conjugate (ADC), MBK-103, which is in development for a range of solid tumor indications. Sofinnova Partners and Mérieux Equity Partners co-led the round.
Orphagen Pharmaceuticals Inc. has presented SF1 (NR5A1) receptor antagonists reported to be useful for the treatment of cancer, endocrine disease and endometriosis.
RSS